barzolvolimab — Topline data
Sep–Oct 2026
Enrollment is complete in our Phase 3 studies in CSU and topline data will be available in September/October 2026.Source filing
CLDX biotech catalysts & pipeline
CELLDEX THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
barzolvolimab — Topline data
late 2026
Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling; Phase 2 topline data in AD expected in late 2026Source filing
barzolvolimab — NDA/BLA submission
2027
Assuming positive Phase 3 data, the Company plans to file a BLA in 2027.Source filing